Half Year results 2012/13

Andrew Williams – Chief Executive

Strategy: sustainable growth, high returns

- Long-term growth drivers
- Competitive advantage in niche markets
- Agile operating structure
- Strategic investment for growth
- Active portfolio management

Half year highlights: Record revenue and profits

Growth & High Returns

+6% £298m Profit +6% £60.8m

ROS +20.4% (LY: 20.5%)

Strategic investment

R&D spend +11% £15m China growth +32%

Acquisitions £66m spend

Good cash performance

Cash flow 99% of profit


Disposals £19m inflow

Dividend +7% interim dps

Group Trading & Financial Review

Record results

Continuing operations H1, 2012/13



^{*} Profit before amortisation of acquired intangibles, acquisition costs and profit on disposal of operations


Revenue growth


Continuing operations H1, 2012/13

	£m	Total	Organic	Organic: Constant Currency
Revenue	298	6%	2%	3%

Evolution of Geographic Revenue


H1 07/08 H1 12/13






Revenue by destination

Revenue and revenue growth, H1, 2012/13 (excluding disposals)




Revenue by destination: organic constant currency

Revenue and revenue growth, H1, 2012/13



Profit* Bridge



^{*} Profit before amortisation of acquired intangibles, acquisition costs and profit on disposal of operations ** Net of financing costs

Halma Half Year results – November 2012

Strong Returns

Return on Sales

➤ Range 18-22%


> H1 2012/13 20.4% (2011/12: 20.5%)

ROCE* 71.6% (2011/12: 68.8%)

ROTIC** 16.4% (2011/12: 16.9%)

* Return on Capital Employed

** Return on Total Invested Capital





Halma Half Year results - November 2012

Sector Trading Review


Sector revenue and profit


HY 2012/13





Health & Analysis: Trading performance






Return on Sales: 22.9%


Health & Analysis: Sub-sector revenue

HY 2012/13: % of sector & % growth





Health & Analysis: Revenue by destination

HY 2012/13: % of sector & % growth (excluding disposals)



Infrastructure Sensors: Trading performance HY 2012/13






Return on Sales: 18.8%


Infrastructure Sensors: Sub-sector revenue

HY 2012/13: % of sector & % growth



Infrastructure Sensors: Revenue by destination


HY 2012/13: % of sector & % growth



Industrial Safety: Trading performance

HY 2012/13 [includes Asset Monitoring, divested in August 2012]






Return on Sales: 24.5%

Industrial Safety: Sub-sector revenue


HY 2012/13: % of sector & % growth*



*Excludes disposal – Asset Monitoring

Industrial Safety: Revenue by destination

HY 2012/13: % of sector & % growth*



*Excludes disposal – Asset Monitoring

Strategic investment

- International Expansion
- Portfolio Management
- People Development
- > Innovation

International expansion: increased collaboration



Portfolio management: SunTech acquisition



SunTech Medical®
Brilliant Blood Pressure Solutions™

"clinical-grade, non-invasive blood pressure (NIBP) products and technology"



People Development















Innovation: New products for Asia, from Asia





Investor Events 2013

Capital Markets event – organic and M&A growth

Location: London Date: 14th February 2013



Location: Orlando, Florida Date: 30th April, 2013

Summary & outlook

- Proven strategy
- Increased investment for growth
- Stronger portfolio
- ➤ H2 order intake in line with expectations
 - Slightly ahead of revenue

"remain on track to make further progress in the second half year"

Questions

Appendices

Currency impacts

		\$	% change		E	% change
Average rates	12/13	11/12		12/13	11/12	
• H1 v £	1.58	1.62	2.5%	1.25	1.14	(9.6%)
• Full Year v £	N/A	1.60		N/A	1.16	
• 1% change* (Annual impact)		\$ (~ 40%	of total)	€	(~20%)	of total)
Revenue		+/- £2	2.3m		+/- £0).8m
Profit		+/- £0).45m		+/- £0).2m

- At \$1.60/€1.25 Average rates for the year 2012/13 profit would reduce by a net amount of £2.6m (2%)* compared with using 2011/12 Fx rates**.
 - * Based on 2012/13 Half year results
 - ** Based on consensus 2012/13 results

Acquisitions and Investment in Associate

	Consideration			
2012/13 Acquisitions	Acquired	Initial £m	Maximum Earn out £m	EBIT* £m
Sensorex	April 12	24	-	2.4
Accutome	April 12	13 **	* 3	1.3
SunTech	May 12	29	4	3.5
		66	7	7.2
Earn-outs re prior year acquisitions				
- Cash		16		
- Loan notes issued		2		
		84	_	
Increased investment in Associate		3	_	
		87		

^{*} at acquisition/disposal run-rate

^{**} includes £1m debt acquired
Halma Half Year results – November 2012

Disposal – Tritech Holdings (Asset Monitoring)

➤ Sold August 2012

		£m
	Proceeds Cash Escrow	19.7 2.1 21.8
>	Net assets/costs Goodwill Gain on disposal	(5.6) (8.0) 8.2

> Annual Revenue: £12.3m, Profit: £2.4m

Impact of M&A

Revenue *

		Actual H1 12/13	Expected H2 12/13	Expected Full Year 12/13
Acquisitions/Disposal	11/12	(1)	(2)	(3)
Acquisitions/Disposal	12/13	14	11	25
		13	9	22

Profit after financing costs *

		Actual H1 12/13	Expected H2 12/13	Expected Full Year 12/13
Acquisitions/Disposal	11/12	0.1	(0.1)	-
Acquisitions/Disposal	12/13	2.4	1.9	4.3
		2.5	1.8	4.3

^{*} at acquisition/disposal run-rate

Pensions

DB plans Deficit	Sept 12	March 12
Assets	158.4	153.0
Liabilities	(199.0)	(186.0)
Deficit	(40.6)	(33.0)

- Closed DB plans to new members in 2003
- Contributions to pay off deficit: £7m/year
 - > Extra £1m in 2012/13 due to Volumatic disposal in March 2012
- > IAS 19 impact 2013/14*: £1m/year

^{*} Comparatives will be restated

Disclaimer

This document contains statements about Halma plc that are or may be forward-looking statements. Forward-looking statements include statements relating to (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; (ii) business and management strategies and the expansion and growth of Halma plc's operations and potential synergies; and (iii) the effects of government regulation on business.

These forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Halma plc. They involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of any such person to be materially different from any results, performance or achievements expressed or implied by such statements. They are based on numerous assumptions regarding the present and future business strategies of such persons and the environment in which each will operate in the future. All subsequent oral or written forward-looking statements attributable to Halma plc or any of its shareholders or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included in this document speak only as of the date they were made and are based on information then available to Halma plc. Investors should not place undue reliance on such forward-looking statements, and Halma plc does not undertake any obligation to update publicly or revise any forward-looking statements.

No representation or warranty, express or implied, is given regarding the accuracy of the information or opinions contained in this document and no liability is accepted by Halma plc or any of its directors, members, officers, employees, agents or advisers for any such information or opinions.

This information is being supplied to you for information purposes only and not for any other purpose. This document and the information contained in it does not constitute or form any part of an offer of, or invitation or inducement to apply for, securities.

The distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of laws of any such other jurisdiction.